

**PEP-Therapy announces the appointments of four key opinion leaders
in its Scientific Advisory Board**

Paris (France), October 6, 2020 - PEP-Therapy, a biotechnology company developing peptides as targeted therapies for oncology, announces the appointments in its Scientific Advisory Board (SAB) of four experts in oncology and peptide development: Pr. Isabelle Ray-Coquard, MD, PhD, Pr. Mario Campone, MD, PhD, Pr. Jean Martinez, PhD, and Dr. Bruno Giroux, MD, PharmD.



Pr. Isabelle Ray-Coquard, MD, PhD is medical oncologist in the Comprehensive Cancer Center Leon Bérard (CLB) and Professor of medical oncology at University Claude Bernard Lyon I. She is the President of the GINECO group (Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein) and the Network Director of the national observatory dedicated to rare ovarian cancer.



Pr. Mario Campone, MD, PhD is the CEO of Institut de Cancérologie de l'Ouest (ICO), he is Hospital Practitioner at the ICO Department of Medical Oncology where he is Head of the Phase I unit certified by the National cancer institute and breast cancer unit. He is also Scientific Director of Cancéropôle Grand Ouest and Professor of medical oncology at the University of Angers.

They will both bring to PEP-Therapy extensive knowledge and experience of therapeutic care in the two indications first targeted by the company: unresectable locally advanced or metastatic triple-negative breast cancer and platinum-resistant ovarian cancer, both having a high medical need.



Pr. Jean Martinez, PhD is Emeritus Professor at the University of Montpellier, Full Professor of organic chemistry and Professor of medicinal chemistry. He is Founder and former Director of the Institut des Biomolécules Max Mousseron (IBMM) where he was Head of the Aminoacids, Peptides and Proteins Department. He was previously President of the European Peptide Society. His research led to the creation of three start-ups as well as two compounds currently on the market.



Dr. Bruno Giroux, MD, PharmD is an independent consultant with more than 35 years of experience in the field of oncology. He started his industrial career at Servier International Research Institute where he first led international projects in oncology R&D and then served as Director of clinical oncology R&D. Then he was successively Medical Director of the Onco-Hematology Business Unit at Roche, Scientific and Medical Manager at Bioalliance, Associate Director Medical Affairs at CAC, a CRO in oncology, and Clinical Development Oncology Manager at Roche.

« We are pleased to welcome Pr. Ray-Coquard, Pr. Campone, Pr. Martinez and Dr. Giroux to our SAB. They are key opinion leaders in their respective fields and they will help PEP-Therapy in the development of our lead compound and our peptide portfolio » commented Antoine Prestat, CEO of PEP-Therapy.

The SAB will complete the current clinical team led by Pr. Christophe Le Tourneau, MD, PhD, senior Medical Oncologist at the Institut Curie, heading the Department of Drug Development and Innovation (D3i) and leading the early phase clinical trials program of the Institut Curie. The SAB will firstly serve as a key strategic resource to PEP-Therapy to perform the Phase Ia/b clinical trial of its PEP-010 first-in-class lead compound, starting at the end of the year, in partnership with two leading cancer centers: Institut Curie and Gustave Roussy.

About PEP-Therapy

PEP-Therapy is an IND-stage medical biotechnology company developing peptides as targeted therapies for severe diseases, with an initial focus on oncology.

PEP-Therapy has developed a Cell Penetrating and Interfering Peptide technology (CP&IP) for the development of its therapeutic products. These innovative molecules penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Founded in January 2014, PEP-Therapy is building on research from Sorbonne University (formerly Pierre and Marie Curie University, UPMC) and Institut Curie. Since its inception, PEP-Therapy has raised 3,1 M€ from Quadrivium 1 seed fund, managed by Seventure Partners, and from Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).

For more details: www.pep-therapy.com

About PEP-010

PEP-010 is PEP-Therapy's first CP&IP-based product, a first-in-class targeted approach to cancer therapy and a pro-apoptotic agent through activation of caspase-9, a major downstream effector of the apoptosis pathway.

PEP-010 has completed preclinical proof-of-concept demonstrating significant anti-tumour activity in patient-derived xenograft (PDX) models. Repeated GLP-toxicity studies showed a good systemic tolerance of the product. PEP-010 is entering first-in-human Phase Ia/b clinical trial at the end of the year in partnership with two leading European cancer hospitals, Institut Curie and Gustave Roussy.

Contact

Antoine Prestat, CEO – +33 1 81 70 76 82 – hello.pep@pep-therapy.com